Can a withdrawn myeloma drug make a comeback with a gentler schedule?
NCT ID NCT05874193
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug belantamab mafodotin, given every 6 weeks alongside a steroid, can be safely used in community clinics for patients with relapsed or refractory multiple myeloma. The drug was previously removed from the market after a confirmatory study failed, but some patients still benefited. The trial will enroll 33 heavily pretreated patients, including elderly and frail individuals, to see if the every-6-week schedule is feasible and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin (a targeted antibody-drug conjugate) plus dexamethasone (a steroid)
What this could lead to
If successful, this could show that giving belantamab mafodotin every 6 weeks in community clinics is safe and effective, offering a more convenient option for patients with advanced multiple myeloma.
What could go wrong
This is a small, early-phase trial (33 people) and the drug was previously withdrawn from the market after a confirmatory study failed. It is unclear if the every-6-week schedule will work as well as the standard every-3-week schedule.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johnston Cancer Center
Smithfield, North Carolina, 27577, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johnston Hematology and Oncology of Clayton
Clayton, North Carolina, 27570, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Maria Parham Hospital
Henderson, North Carolina, 27536, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Scotland Health Care System
Laurinburg, North Carolina, 28352, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UNC Health Southeastern
Lumberton, North Carolina, 28358, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••